Get 40% Off
🔥 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

Lazard Or Waddell & Reed: Which Is A Better Investment Pick?

Published 03/28/2018, 09:59 PM
Updated 07/09/2023, 06:31 AM
LAZ
-
WDR
-

Benefits from a stabilizing economy and gradually improving interest-rate scenario have positioned the investment management industry well. Investment managers are expected to benefit from a rising rate environment in the soon-to-be concluded quarter.

Additionally, most investment managers have waived off the majority of their fees with the rates rising since 2016. This decline in fee waivers is expected to aid the company’s top-line growth in their upcoming results.

Despite inflation-related issues and increasing chances of economic uncertainty, most of the asset managers have performed decently in their assets under management numbers in the first two months of the quarter. Moreover, with expectations of increased volatility, performance of asset managers is expected to be decent.

Therefore, we are focusing on two investment managers, Waddell & Reed Financial, Inc. (NYSE:WDR) and Lazard Ltd (NYSE:LAZ) .

Waddell & Reed, with a market cap of $1.8 billion, provides a wide range of investment management and advisory services in the United States. On the other hand, Lazard operates as a financial advisory and asset management firm globally and has a market cap of $6.6 billion.

Waddell & Reed sports a Zacks Rank #1 (Strong Buy) with a Value Score of A. Our research shows that stocks with a Value Score of A or B, when combined with a Zacks Rank #1 or 2 (Buy), offer the best upside potential.

Lazard has a Zacks Rank #2 with a Value Score of C. You can see the complete list of today’s Zacks #1 Rank stocks here.

Though both asset managers have similar business trends, deeper research into the financials will help decide which investment option is better.

Price Performance

Though both the asset managers have underperformed the industry (up 17.3%) over the past year, they have gained decently. While shares of Waddell & Reed have gained 16.1%, Lazard has spiked 12.4%. So, Waddell & Reed performed better than Lazard.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .



Dividend Yield

Both the companies have been deploying capital in terms of dividend payments to enhance shareholder value. Waddell & Reed has a current dividend yield of 5.06% while Lazard has a dividend yield of 3.17%.

Although both the stocks’ dividend yield is better than the industry’s average of 2.54%, shareholders of Waddell & Reed gain more.



Leverage Ratio

Both Waddell & Reed and Lazard have higher debt-to-equity ratio compared with the industry average of 0.09. But Waddell & Reed with a ratio of 0.11 has an edge over Lazard with the same of 0.95.

Return on Equity (ROE)

ROE is a measure of a company’s efficiency in utilizing shareholder’s funds. ROE for the trailing 12-months for Waddell & Reed and Lazard is 16.63% and 38.93%, respectively. While both stocks have scored above the industry’s level of 12.46%, Lazard reinvests its earnings more efficiently.



Earnings Estimate Revisions & Growth Projections

The Zacks Consensus Estimate for 2018 earnings of Waddell & Reed has increased 6.2%, over the last 30 days. On the other hand, the same for Lazard has remained stable for 2018, over the same time frame.

Moreover, earnings for Waddell & Reed for the current year are projected to jump 16.7% year over year. For Lazard, the Zacks Consensus Estimate stands at $3.99 for 2018, reflecting a year-over-year increase of 5.6%.

Therefore, Waddell & Reed has an edge here as well.

Conclusion

Our comparative analysis shows that Waddell & Reed is better positioned than Lazard when considering price performance, dividend yield, leverage ratio, earnings growth expectations and Value Score. Lazard wins on reinvesting potential.

Investor Alert: Breakthroughs Pending

A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.

Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.

Click here to see them >>

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Waddell & Reed Financial, Inc. (WDR): Free Stock Analysis Report

Lazard Ltd (LAZ): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.